Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
This article was originally published in PharmAsia News
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
You may also be interested in...
How Celltrion and Hospira will share the European market remains to be seen, but Celltrion says the partners will support each other in taking on J&J’s Remicade. The Korean company also files for approval of infliximab in Japan, setting up another potential battleground on biosimilars.
Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.